81: Pharmacogenetics in a Large Chinese Cohort

Wei C-Y et al et al., Nature Communications - Retrospective analysis of 486,956 Han Chinese from the Taiwan Precision Medicine Initiative evaluated prevalence and clinical impact of actionable pharmacogenetic (PGx) variants across 19 genes and 58 drugs, with focused outcome analyses for four gene–drug pairs. Findings confirm widespread PGx variation and statistically increased risks for some adverse events, but absolute excess risks were small and most variant carriers tolerated therapy. Key terms: pharmacogenetics, Taiwan Precision Medicine Initiative, clopidogrel, azathioprine, statins. Study Highlights:In 486,956 TPMI participants, 99.9% carried at least one actionable PGx variant and the mean per person was 4.3 variants. Nearly half had been prescribed at least one drug with PGx recommendations and 17.8% received high-risk drugs without prior genotyping. Analyses of CYP2C19–clopidogrel, NUDT15/TPMT–azathioprine, ABCG2/CYP2C9/SLCO1B1–statins, and CYP2C9–NSAIDs validated genotype–ADE associations but showed small absolute excess risks and that most carriers did not experience adverse events. The results highlight implementation complexity and the need to integrate PGx with clinical factors. Conclusion:Actionable PGx variants are ubiquitous in this Han Chinese cohort and confer statistically significant risks for drug-related adverse events in several gene–drug pairs, but absolute risk increases are modest and most carriers tolerate treatment; clinical implementation should be cautious and combined with clinical, environmental and additional genetic data. Music:Enjoy the music based on this article at the end of the episode. Article title:Clinical impact of pharmacogenetic risk variants in a large chinese cohort First author:Wei C-Y et al Journal:Nature Communications DOI:10.1038/s41467-025-61644-x Reference:Wei C-Y et al., Clinical impact of pharmacogenetic risk variants in a large Chinese cohort. Nature Communications (2025). doi:10.1038/s41467-025-61644-x License:This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support:Base by Base – Stripe donations: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 Official website https://basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/pgx-tpmi-chinese-cohort-2025 QC:This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-07-20. QC Scope:- article metadata and core scientific claims from the narration- excludes analogies, intro/outro, and music- transcript coverage: Audited the transcript's discussion of the TPMI cohort (size, data sources), the four gene–drug pairs (AZA/NUDT15-TPMT, clopidogrel/CYP2C19, statins/ABCG2-CYP2C9/SLCO1B1, NSAIDs/CYP2C9), the core results (relative vs absolute risk), and the study limitations (CYP2D6 exclusion, phenoconversion, EMR data scope).- transcript topics: TPMI cohort size and data sources (Han Chinese, EMR, SNP arrays); Four pharmacogenes–drug pairs: AZA (NUDT15/TPMT), clopidogrel (CYP2C19), statins (ABCG2/CYP2C9/SLCO1B1), NSAIDs (CYP2C9); Relative vs absolute risk interpretation and clinical utility of PGx; Limitations and future directions (phenoconversion, CYP2D6 exclusion, SNP-array limits, EMR data limits) QC Summary:- factual score: 10/10- metadata score: 10/10- supported core claims: 6- claims flagged for review: 0- metadata checks passed: 4- metadata issues found: 0 Metadata Audited:- article_doi- article_title- article_journal-...